Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 36 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Atezolizumab in Addition to Chemotherapy for Stage IV Squamous Non-Small Cell Lung Cancer – First Line	Atezolizumab (Tecentriq; MPDL3280A)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2018	View \| Download
Atezolizumab in addition to cobimetinib and vemurafenib for BRAF mutated metastatic melanoma	Atezolizumab (Tecentriq; MPDL3280A) , Cobimetinib (Cotellic; GDC-0973; cobimetinib hemifumarate) , Vemurafenib (Zelboraf; PLX4032; R7204; RO5185426; PLX-4032; RG7204)	Melanoma	Skin Cancer	2019	View \| Download
Atezolizumab in addition to paclitaxel for inoperable, locally advanced or metastatic triple negative breast cancer – first-line	Atezolizumab (Tecentriq; MPDL3280A) , Paclitaxel (Taxol; paclitaxel albumin)	Breast cancer	Breast Cancer	2019	View \| Download
Atezolizumab in addition to paclitaxel, carboplatin and bevacizumab for epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer – first-line	Atezolizumab (Tecentriq; MPDL3280A) , Bevacizumab (Avastin; R 435; RG 405; RG 435) , Carboplatin (Paraplatin) , Paclitaxel (Taxol; paclitaxel albumin)	Epithelial ovarian cancer , Fallopian tube cancer , primary peritoneal cancer	Female Reproductive Cancer	2019	View \| Download
Atezolizumab in combination with bevacizumab for untreated unresectable or advanced hepatocellular carcinoma	Atezolizumab (Tecentriq; MPDL3280A) , Bevacizumab (Avastin; R 435; RG 405; RG 435)	Hepatocellular carcinoma (HCC)	Gastrointestinal Cancer	2019	View \| Download
Atezolizumab in combination with chemotherapy for non-small-cell lung cancer- neoadjuvant and adjuvant	Atezolizumab (Tecentriq; MPDL3280A)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2020	View \| Download
Atezolizumab in combination with cobimetinib for BRAF wild-type metastatic melanoma – first line	Atezolizumab (Tecentriq; MPDL3280A) , Cobimetinib (Cotellic; GDC-0973; cobimetinib hemifumarate)	Melanoma	Skin Cancer	2018	View \| Download
Atezolizumab in combination with nab-paclitaxel as neoadjuvant treatment for early stage triple-negative breast cancer	Atezolizumab (Tecentriq; MPDL3280A) , Nab-Paclitaxel (Abraxane; ABI 007; ABI-007)	Breast cancer	Breast Cancer	2018	View \| Download
Atezolizumab in combination with Nab-paclitaxel for unresectable, locally advanced or metastatic triple-negative breast cancer – first line	Atezolizumab (Tecentriq; MPDL3280A) , Nab-Paclitaxel (Abraxane; ABI 007; ABI-007)	Breast cancer	Breast Cancer	2018	View \| Download
Atezolizumab in combination with platinum-based chemotherapy for untreated locally advanced or metastatic urothelial cancer – first line	Atezolizumab (Tecentriq; MPDL3280A)	Urothelial cancer	Urological Cancer	2020	View \| Download